Excessive uterine bleeding during MENSTRUATION.
Intrauterine devices that release contraceptive agents.
Procedures used for the targeted destruction of the mucous membrane lining of the uterine cavity.
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.
Endoscopic examination, therapy or surgery of the interior of the uterus.
Benzenesulfonate derivative used as a systemic hemostatic.
Excision of the uterus.
Tumors or cancer of the UTERUS.
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.
Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.
Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.
Antifibrinolytic hemostatic used in severe hemorrhage.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
Variations of menstruation which may be indicative of disease.
Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities.
A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.
Dilatation of the cervix uteri followed by a scraping of the endometrium with a curette.
The hollow thick-walled muscular organ in the female PELVIS. It consists of the fundus (the body) which is the site of EMBRYO IMPLANTATION and FETAL DEVELOPMENT. Beyond the isthmus at the perineal end of fundus, is CERVIX UTERI (the neck) opening into VAGINA. Beyond the isthmi at the upper abdominal end of fundus, are the FALLOPIAN TUBES.
Intrauterine contraceptive devices that depend on the release of metallic copper.
Painful menstruation.

Angiogenesis, vascular endothelial growth factor and the endometrium. (1/195)

Angiogenesis is an essential component of endometrial renewal. The formation of new vessels depends on interactions between various hormones and growth factors, and this review focuses on the expression of angiogenic growth factors in the human endometrium. Peptide and non-peptide angiogenic factors interact during endometrial renewal, including epidermal growth factor (EGF), transforming growth factors (e.g. TGF-beta), platelet-derived endothelial growth factor/thymidine phosphorylase (PD-ECGF/TP), tumour necrosis growth factors and vascular endothelial growth factor (VEGF). Their role in the proliferation and migration of endothelial cells from pre-existing vessels is described, concentrating on VGEF and its receptors (VEG-R1 and -R2), and the fibroblast growth factor (FGF) family. The actions of the products of the VEGF gene are outlined, and the hormonal and non-hormonal control of their localization in the human endometrium and biological actions on vasculature and coagulation are described. Finally, the role of VEGF in menorrhagia is assessed.  (+info)

SF 36 health survey questionnaire: I. Reliability in two patient based studies. (2/195)

OBJECTIVE: To assess the reliability of the SF 36 health survey questionnaire in two patient populations. DESIGN: Postal questionnaire followed up, if necessary, by two reminders at two week intervals. Retest questionnaires were administered postally at two weeks in the first study and at one week in the second study. SETTING: Outpatient clinics and four training general practices in Grampian region in the north east of Scotland (study 1); a gastroenterology outpatient clinic in Aberdeen Royal Hospitals Trust (study 2). PATIENTS: 1787 patients presenting with one of four conditions: low back pain, menorrhagia, suspected peptic ulcer, and varicose veins and identified between March and June 1991 (study 1) and 573 patients attending a gastroenterology clinic in April 1993. MAIN MEASURES: Assessment of internal consistency reliability with Cronbach's alpha coefficient and of test-retest reliability with the Pearson correlation coefficient and confidence interval analysis. RESULTS: In study 1, 1317 of 1746 (75.4%) correctly identified patients entered the study and in study 2, 549 of 573 (95.8%). Both methods of assessing reliability produced similar results for most of the SF 36 scales. The most conservative estimates of reliability gave 95% confidence intervals for an individual patient's score difference ranging from -19 to 19 for the scales measuring physical functioning and general health perceptions, to -65.7 to 65.7 for the scale measuring role limitations attributable to emotional problems. In a controlled clinical trial with sample sizes of 65 patients in each group, statistically significant differences of 20 points can be detected on all eight SF 36 scales. CONCLUSIONS: All eight scales of the SF 36 questionnaire show high reliability when used to monitor health in groups of patients, and at least four scales possess adequate reliability for use in managing individual patients. Further studies are required to test the feasibility of implementing the SF 36 and other outcome measures in routine clinical practice within the health service.  (+info)

SF 36 health survey questionnaire: II. Responsiveness to changes in health status in four common clinical conditions. (3/195)

OBJECTIVE: To assess the responsiveness of the SF 36 health survey questionnaire to changes in health status over time for four common clinical conditions. DESIGN: Postal questionnaires at baseline and after one year's follow up, with two reminders at two week intervals if necessary. SETTING: Clinics and four training general practices in Grampian region in the north east of Scotland. PATIENTS: More than 1,700 patients aged 16 to 86 years with one of four conditions: low back pain, menorrhagia, suspected peptic ulcer, and varicose veins; and a random sample of 900 members of the local general population for comparison. MAIN MEASURES: A transition question measuring change in health and the eight scales of the SF 36 health survey questionnaire; standardised response means (mean change in score for a scale divided by the standard deviation of the change in scores) used to quantify the instrument's responsiveness to changes in perceived health status, and comparison of patient scores at baseline and follow up with those of the general population. RESULTS: The response rate exceeded 75% in a patient population. Changes across the SF 36 questionnaire were associated with self reported changes in health, as measured by the transition question. The questionnaire showed significant improvements in health status for all four clinical conditions, whether in referred or non-referred patients. For patients with suspected peptic ulcer and varicose veins the SF 36 profiles at one year approximate to the general population. CONCLUSIONS: These results provide the first evidence of the responsiveness of the SF 36 questionnaire to changes in perceived health status in a patient population in the United Kingdom.  (+info)

Making sense of ambiguity: evaluation in internal reliability and face validity of the SF 36 questionnaire in women presenting with menorrhagia. (4/195)

OBJECTIVE: To determine the face validity and internal reliability of the short form 36 (SF 36) health survey questionnaire in women presenting with menorrhagia. DESIGN: Postal survey of women recruited by their general practitioners followed by interviews of a selected subsample. PATIENTS: 348 women who had consulted their general practitioner with excessive menstrual bleeding and completed questionnaires after treatment. 49 women selected from this group were interviewed in depth about their health status, and requested to complete the SF 36 questionnaire. MAIN MEASURES: Subjective accounts of functioning and wellbeing as measured by the eight scales of the SF 36 questionnaire. RESULTS: Data from the postal survey indicated that the inverted question markgeneral health perceptions inverted question mark and inverted question markmental health inverted question mark scales of the SF 36 questionnaire had lower internal reliability coefficients than documented elsewhere. In the follow up interviews several questions on the SF 36 questionnaire were commented on as inappropriate or difficult to answer for patients with heavy menstrual bleeding. CONCLUSIONS: Some questions on the SF 36 questionnaire were difficult to answer for this group of patients. Such problems can adversely effect the validity of the measure. It is suggested that comments of patients upon measures such as the SF 36 questionnaire could both determine the appropriateness of such measures for given studies and influence questionnaire design.  (+info)

Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. (5/195)

Although the role of the reproductive hormone, relaxin, in rodents is well documented, its potential contribution to human reproduction is less well defined. In this study, we examine the effects of relaxin on human endometrial cells in vitro and describe the clinical effects of relaxin on menstrual flow in women. In cultured endometrial cells, relaxin specifically induces the expression of an angiogenic agent, vascular endothelial growth factor (VEGF). cAMP is implicated as a second messenger involved in VEGF stimulation. VEGF expression is temporally regulated in the endometrium, and our results suggest that relaxin, which is secreted by the corpus luteum and is present in the endometrium during the menstrual cycle and pregnancy, may be involved in regulating endometrial VEGF expression. Relaxin was recently tested in a clinical trial for efficacy in the treatment of progressive systemic sclerosis, and was administered at levels up to 10 times higher than that measured during pregnancy. The most frequent relaxin-related adverse event reported during the course of the study was the onset of menometrorrhagia, defined in this study as heavier-than-usual or irregular menstrual bleeding. The intensification of menstrual flow observed in these patients is consistent with the hypothesis that relaxin mediates neovascularization of the endometrial lining.  (+info)

Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. (6/195)

OBJECTIVE: To determine whether an educational package could influence the management of menorrhagia, increase the appropriateness of choice of non-hormonal treatment, and reduce referral rates from primary to secondary care. DESIGN: Randomised controlled trial. SETTING: General practices in East Anglia. SUBJECTS: 100 practices (348 doctors) in primary care were recruited and randomised to intervention (54) and control (46). INTERVENTIONS: An educational package based on principles of "academic detailing" with independent academics was given in small practice based interactive groups with a visual presentation, a printed evidence based summary, a graphic management flow chart, and a follow up meeting at 6 months. OUTCOME MEASURES: All practices recorded consultation details, treatments offered, and outcomes for women with regular heavy menstrual loss (menorrhagia) over 1 year. RESULTS: 1001 consultation data sheets for menorrhagia were returned. There were significantly fewer referrals (20% v 29%; odds ratio 0. 64; 95% confidence interval 0.41 to 0.99) and a significantly higher use of tranexamic acid (odds ratio 2.38; 1.61 to 3.49) in the intervention group but no overall difference in norethisterone treatment compared with controls. There were more referrals when tranexamic acid was given with norethisterone than when it was given alone. Those practices reporting fewer than 10 cases showed the highest increase in prescribing of tranexamic acid. CONCLUSIONS: The educational package positively influenced referral for menorrhagia and treatment with appropriate non-hormonal drugs.  (+info)

Menorrhagia and uterine artery blood flow. (7/195)

Menorrhagia is a significant problem in women of reproductive age. In half of the cases no specific aetiology is known. Vascular factors play a role but remain poorly understood. We chose to study whether any association exists between the flow impedance of uterine arteries and the amount of menstrual blood loss. The study population consisted of 60 spontaneously menstruating 35- to 49-year-old women without endometrial hyperplasia, polyps, or submucous fibroids. The pulsatility index (PI) from uterine arteries, arcuate arteries, and radial arteries was measured by transvaginal colour Doppler. Menstrual blood loss was measured by the alkaline haematin method. A significant inverse correlation was found between uterine artery PI and the amount of menstrual blood loss, suggesting that women with lower uterine flow impedance bleed more. A regression model confirmed that this association was specific and not explained by uterine size, fibroids or any other of the 11 potential confounders included in the model. The correlation between uterine artery PI and amount of menstrual blood loss suggests that vascular factors may be involved in the pathogenesis of menorrhagia.  (+info)

Nitric oxide synthase expression and steroid regulation in the uterus of women with menorrhagia. (8/195)

Menorrhagia (excessive menstrual bleeding) is a common clinical problem of unknown aetiology. The free-radical and vasodilator nitric oxide (NO) relaxes the myometrial smooth muscle and is a strong candidate for the cause of excessive blood loss in menorrhagic patients. The aim of this study was to measure NO production in women with and without menorrhagia to detect nitric oxide synthase (NOS) isoforms in uterine cells and to investigate any steroid effects on myometrial NOS expression. We showed for the first time that menorrhagic endometrium produces significantly higher amounts of NOx (the sum of NO(2-) and NO(3-)) than control endometrium (P < 0.01). Inducible NOS (iNOS) protein was detected by immunoblotting in endometrial and myometrial tissue extracts. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) experiments revealed an induction of myometrial smooth muscle endothelial NOS (eNOS) expression by progesterone and 17beta-oestradiol, while myometrial iNOS expression was unaffected by steroid hormones. These results are consistent with the hypothesis that NO plays a role in excessive menstrual bleeding and provide the first evidence on steroid regulation of eNOS in the human non-pregnant uterus.  (+info)

Menorrhagia is a medical term used to describe abnormally heavy or prolonged menstrual periods. It's often characterized by the loss of an excessive amount of menstrual blood (usually more than 80 ml) and can last longer than normal, typically over seven days. This condition can have significant impacts on a woman's quality of life, causing fatigue, distress, and restrictions in daily activities due to the need for frequent pad or tampon changes.

The causes of menorrhagia are varied and can include hormonal imbalances, uterine fibroids or polyps, endometrial hyperplasia, pelvic inflammatory disease, pregnancy complications, certain medications, and underlying medical conditions such as coagulopathies or thyroid disorders. In some cases, the cause may remain undetermined even after a thorough evaluation.

Treatment options for menorrhagia depend on the underlying cause and range from medication management with hormonal therapies, nonsteroidal anti-inflammatory drugs (NSAIDs), or tranexamic acid to procedural interventions like endometrial ablation, hysteroscopic resection of polyps or fibroids, or ultimately hysterectomy in severe cases. It is essential for individuals experiencing menorrhagia to consult with their healthcare provider to determine the best course of action based on their specific situation and medical history.

An intrauterine device (IUD) is a small, T-shaped birth control device that is inserted into the uterus to prevent pregnancy. A medicated IUD is a type of IUD that contains hormones, which are released slowly over time to provide additional benefits beyond just contraception.

There are two types of medicated IUDs available in the US market: levonorgestrel-releasing intrauterine system (LNG-IUS) and the copper intrauterine device (Cu-IUD). The LNG-IUS releases a progestin hormone called levonorgestrel, which thickens cervical mucus to prevent sperm from reaching the egg, thins the lining of the uterus to make it less likely for a fertilized egg to implant, and can also inhibit ovulation in some women. The Cu-IUD is non-hormonal and works by releasing copper ions that create a toxic environment for sperm, preventing them from reaching the egg.

Medicated IUDs are highly effective at preventing pregnancy, with typical use failure rates of less than 1% per year. They can remain in place for several years, depending on the brand, and can be removed at any time by a healthcare provider if a woman wants to become pregnant or experience side effects. Common side effects of medicated IUDs may include irregular menstrual bleeding, cramping, and spotting between periods, although these tend to improve over time.

Endometrial ablation is a medical procedure that involves the removal or destruction of the endometrium, which is the lining of the uterus. This procedure is typically used to treat heavy menstrual bleeding that has not responded to other forms of treatment, such as medication. There are several techniques for performing endometrial ablation, including:

1. Hysteroscopy: This technique uses a thin, lighted tube with a camera called a hysteroscope, which is inserted through the cervix into the uterus. The surgeon can then see the endometrium and use instruments to remove or destroy it.
2. Electrosurgical ablation: This technique uses an electrical current to burn away the endometrium. A probe is inserted through the cervix into the uterus, and the electrical current is passed through the probe to heat and destroy the endometrial tissue.
3. Freezing: Also known as cryoablation, this technique involves freezing the endometrium with a probe that is inserted through the cervix into the uterus. The probe is cooled to a very low temperature, which destroys the endometrial tissue.
4. Radiofrequency ablation: This technique uses radiofrequency energy to heat and destroy the endometrium. A probe is inserted through the cervix into the uterus, and the radiofrequency energy is delivered to the endometrial tissue.
5. Balloon ablation: This technique involves inserting a balloon into the uterus and filling it with fluid that is heated to a high temperature. The heat from the fluid destroys the endometrium.
6. Microwave ablation: This technique uses microwave energy to heat and destroy the endometrium. A probe is inserted through the cervix into the uterus, and the microwave energy is delivered to the endometrial tissue.

It's important to note that endometrial ablation is not a form of birth control, and women who undergo this procedure may still become pregnant. However, pregnancy after endometrial ablation can be dangerous for both the mother and the fetus, so it is important to use reliable forms of contraception after the procedure.

Mefenamic Acid is a non-steroidal anti-inflammatory drug (NSAID) commonly used for its analgesic, antipyretic, and anti-inflammatory properties. It works by inhibiting the enzyme cyclooxygenase (COX), which is responsible for prostaglandin synthesis, a key player in pain and inflammation processes.

Mefenamic Acid is primarily used to treat mild to moderate pain, including menstrual cramps, primary dysmenorrhea, post-operative pain, and various types of inflammatory conditions such as rheumatoid arthritis and osteoarthritis.

Common side effects may include gastrointestinal disturbances like nausea, vomiting, diarrhea, or abdominal pain. Long-term use of Mefenamic Acid has been associated with increased risks of cardiovascular events, gastrointestinal ulcers, and bleeding. Therefore, it is essential to follow the recommended dosage and consult a healthcare professional for appropriate usage and potential interactions with other medications.

Levonorgestrel is a synthetic form of the natural hormone progesterone, which is used in various forms of birth control and emergency contraceptives. It works by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

Medically, Levonorgestrel is classified as a progestin and is available in various forms, including oral tablets, intrauterine devices (IUDs), and emergency contraceptive pills. It may also be used to treat endometriosis, irregular menstrual cycles, and heavy menstrual bleeding.

It's important to note that while Levonorgestrel is a highly effective form of birth control when used correctly, it does not protect against sexually transmitted infections (STIs). Therefore, condoms should still be used during sexual activity if there is any risk of STI transmission.

Leiomyoma is a benign (non-cancerous) tumor that originates from the smooth muscle cells. It most commonly occurs in the uterus, where it is also known as a fibroid, but can also develop in other parts of the body such as the skin, gastrointestinal tract, and genitourinary system. Leiomyomas are typically slow-growing and often cause no symptoms, although they can lead to various complications depending on their size and location. Treatment options for leiomyomas include surveillance, medication, or surgical removal.

Menstruation is the regular, cyclical shedding of the uterine lining (endometrium) in women and female individuals of reproductive age, accompanied by the discharge of blood and other materials from the vagina. It typically occurs every 21 to 35 days and lasts for approximately 2-7 days. This process is a part of the menstrual cycle, which is under the control of hormonal fluctuations involving follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen, and progesterone.

The menstrual cycle can be divided into three main phases:

1. Menstruation phase: The beginning of the cycle is marked by the start of menstrual bleeding, which signals the breakdown and shedding of the endometrium due to the absence of pregnancy and low levels of estrogen and progesterone. This phase typically lasts for 2-7 days.

2. Proliferative phase: After menstruation, under the influence of rising estrogen levels, the endometrium starts to thicken and regenerate. The uterine lining becomes rich in blood vessels and glands, preparing for a potential pregnancy. This phase lasts from day 5 until around day 14 of an average 28-day cycle.

3. Secretory phase: Following ovulation (release of an egg from the ovaries), which usually occurs around day 14, increased levels of progesterone cause further thickening and maturation of the endometrium. The glands in the lining produce nutrients to support a fertilized egg. If pregnancy does not occur, both estrogen and progesterone levels will drop, leading to menstruation and the start of a new cycle.

Understanding menstruation is essential for monitoring reproductive health, identifying potential issues such as irregular periods or menstrual disorders, and planning family planning strategies.

Hysteroscopy is a diagnostic procedure that allows healthcare professionals to examine the interior of the uterus (hyster(o)- and -scopy from Greek "womb" + "examination"). It is performed using a hysteroscope, which is a thin, lighted tube with a camera attached to its end. The hysteroscope is inserted through the vagina and cervix into the uterus, enabling the visualization of the uterine cavity and the detection of any abnormalities, such as polyps, fibroids, or structural issues like a septum.

Hysteroscopy can be performed in a doctor's office or an outpatient surgical center under local, regional, or general anesthesia depending on the situation and patient comfort. The procedure may also be used for minor surgical interventions, such as removing polyps or fibroids, or to assist with other procedures like laparoscopy.

In summary, hysteroscopy is a medical examination of the uterine cavity using a thin, lighted tube called a hysteroscope, which can aid in diagnosing and treating various conditions affecting the uterus.

Ethamsylate is a medication that belongs to a class of drugs known as anti-fibrinolytics. It works by helping to prevent the breakdown of blood clots and promoting the healing of damaged blood vessels. Ethamsylate is often used in the treatment of conditions associated with bleeding, such as menorrhagia (heavy menstrual periods) and various types of hemorrhage (severe bleeding).

The chemical name for Ethamsylate is diethylammonium 3,4-dimethoxybenzenesulfonate. It is available in oral tablet form and is typically prescribed to be taken two to three times a day, depending on the severity of the condition being treated. As with any medication, it's important to follow your healthcare provider's instructions carefully when taking Ethamsylate.

While Ethamsylate can be effective in treating certain types of bleeding, it is not without potential side effects. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. In rare cases, more serious side effects such as allergic reactions, kidney damage, or changes in blood pressure may occur. If you experience any unusual symptoms while taking Ethamsylate, it's important to contact your healthcare provider right away.

A hysterectomy is a surgical procedure that involves the removal of the uterus (womb). Depending on the specific medical condition and necessity, a hysterectomy may also include the removal of the ovaries, fallopian tubes, and surrounding tissues. There are different types of hysterectomies, including:

1. Total hysterectomy: The uterus and cervix are removed.
2. Supracervical (or subtotal) hysterectomy: Only the upper part of the uterus is removed, leaving the cervix intact.
3. Radical hysterectomy: This procedure involves removing the uterus, cervix, surrounding tissues, and the upper part of the vagina. It is typically performed in cases of cervical cancer.
4. Oophorectomy: The removal of one or both ovaries can be performed along with a hysterectomy depending on the patient's medical condition and age.
5. Salpingectomy: The removal of one or both fallopian tubes can also be performed along with a hysterectomy if needed.

The reasons for performing a hysterectomy may include but are not limited to: uterine fibroids, heavy menstrual bleeding, endometriosis, adenomyosis, pelvic prolapse, cervical or uterine cancer, and chronic pelvic pain. The choice of the type of hysterectomy depends on the patient's medical condition, age, and personal preferences.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

The endometrium is the innermost layer of the uterus, which lines the uterine cavity and has a critical role in the menstrual cycle and pregnancy. It is composed of glands and blood vessels that undergo cyclic changes under the influence of hormones, primarily estrogen and progesterone. During the menstrual cycle, the endometrium thickens in preparation for a potential pregnancy. If fertilization does not occur, it will break down and be shed, resulting in menstruation. In contrast, if implantation takes place, the endometrium provides essential nutrients to support the developing embryo and placenta throughout pregnancy.

Ecchymosis is a medical term that refers to a discoloration of the skin caused by the leakage of blood from ruptured blood vessels into the tissues beneath. It is typically caused by trauma or injury to the affected area, which results in the escape of blood from the damaged blood vessels. The escaped blood collects under the skin, causing a bruise or a purple, blue, or blackish patch on the skin's surface.

Ecchymosis can occur anywhere on the body and can vary in size and shape depending on the extent of the injury. While ecchymosis is generally harmless and resolves on its own within a few days to a week, it can be a sign of an underlying medical condition, such as a bleeding disorder or a blood vessel abnormality. In these cases, further evaluation and treatment may be necessary.

Contraceptive agents, female, are medications or devices specifically designed to prevent pregnancy in women. They work by interfering with the normal process of ovulation, fertilization, or implantation of a fertilized egg in the uterus. Some common examples of female contraceptive agents include:

1. Hormonal methods: These include combined oral contraceptives (COCs), progestin-only pills, patches, vaginal rings, and hormonal implants. They contain synthetic forms of the female hormones estrogen and/or progesterone, which work by preventing ovulation, thickening cervical mucus to make it harder for sperm to reach the egg, or thinning the lining of the uterus to prevent implantation of a fertilized egg.
2. Intrauterine devices (IUDs): These are small, T-shaped devices made of plastic or copper that are inserted into the uterus by a healthcare provider. They release hormones or copper ions that interfere with sperm movement and prevent fertilization or implantation.
3. Barrier methods: These include condoms, diaphragms, cervical caps, and sponges. They work by physically preventing sperm from reaching the egg.
4. Emergency contraception: This includes medications such as Plan B or Ella, which can be taken up to 5 days after unprotected sex to prevent pregnancy. They work by delaying ovulation or preventing fertilization of the egg.
5. Fertility awareness-based methods (FABMs): These involve tracking a woman's menstrual cycle and avoiding sexual intercourse during her fertile window. Some FABMs also involve using barrier methods during this time.

It is important to note that different contraceptive agents have varying levels of effectiveness, side effects, and risks. Women should consult with their healthcare provider to determine the best method for their individual needs and circumstances.

Uterine hemorrhage, also known as uterine bleeding or gynecological bleeding, is an abnormal loss of blood from the uterus. It can occur in various clinical settings such as menstruation (known as menorrhagia), postpartum period (postpartum hemorrhage), or in non-pregnant women (dysfunctional uterine bleeding). The bleeding may be light to heavy, intermittent or continuous, and can be accompanied by symptoms such as pain, dizziness, or fainting. Uterine hemorrhage is a common gynecological problem that can have various underlying causes, including hormonal imbalances, structural abnormalities, coagulopathies, and malignancies. It is important to seek medical attention if experiencing heavy or prolonged uterine bleeding to determine the cause and receive appropriate treatment.

Tranexamic acid is an antifibrinolytic medication that is used to reduce or prevent bleeding. It works by inhibiting the activation of plasminogen to plasmin, which is a protease that degrades fibrin clots. By preventing the breakdown of blood clots, tranexamic acid helps to reduce bleeding and promote clot formation.

Tranexamic acid is available in various forms, including tablets, capsules, and injectable solutions. It is used in a variety of clinical settings, such as surgery, trauma, and heavy menstrual bleeding. The medication can be taken orally or administered intravenously, depending on the severity of the bleeding and the patient's medical condition.

Common side effects of tranexamic acid include nausea, vomiting, diarrhea, and headache. Less commonly, the medication may cause allergic reactions, visual disturbances, or seizures. It is important to follow the prescribing physician's instructions carefully when taking tranexamic acid to minimize the risk of side effects and ensure its safe and effective use.

Antifibrinolytic agents are a class of medications that inhibit the breakdown of blood clots. They work by blocking the action of enzymes called plasminogen activators, which convert plasminogen to plasmin, the main enzyme responsible for breaking down fibrin, a protein that forms the framework of a blood clot.

By preventing the conversion of plasminogen to plasmin, antifibrinolytic agents help to stabilize existing blood clots and prevent their premature dissolution. These medications are often used in clinical settings where excessive bleeding is a concern, such as during or after surgery, childbirth, or trauma.

Examples of antifibrinolytic agents include tranexamic acid, aminocaproic acid, and epsilon-aminocaproic acid. While these medications can be effective in reducing bleeding, they also carry the risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, due to their pro-coagulant effects. Therefore, they should be used with caution and only under the close supervision of a healthcare provider.

Menstruation disturbances, also known as menstrual disorders, refer to any irregularities or abnormalities in a woman's menstrual cycle. These disturbances can manifest in various ways, including:

1. Amenorrhea: The absence of menstrual periods for three consecutive cycles or more in women of reproductive age.
2. Oligomenorrhea: Infrequent or light menstrual periods that occur at intervals greater than 35 days.
3. Dysmenorrhea: Painful menstruation, often accompanied by cramping, pelvic pain, and other symptoms that can interfere with daily activities.
4. Menorrhagia: Heavy or prolonged menstrual periods that last longer than seven days or result in excessive blood loss, leading to anemia or other health complications.
5. Polymenorrhea: Abnormally frequent menstrual periods that occur at intervals of 21 days or less.
6. Metrorrhagia: Irregular and unpredictable vaginal bleeding between expected menstrual periods, which can be caused by various factors such as hormonal imbalances, infections, or structural abnormalities.

Menstruation disturbances can have significant impacts on a woman's quality of life, fertility, and overall health. They may result from various underlying conditions, including hormonal imbalances, polycystic ovary syndrome (PCOS), thyroid disorders, uterine fibroids, endometriosis, or sexually transmitted infections. Proper diagnosis and treatment of the underlying cause are essential for managing menstruation disturbances effectively.

Progesterone congeners refer to synthetic or naturally occurring compounds that are structurally similar to progesterone, a steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis. These compounds have similar chemical structures to progesterone and may exhibit similar physiological activities, although they can also have unique properties and uses. Examples of progesterone congeners include various synthetic progestins used in hormonal contraceptives and other medical treatments.

Norethindrone is a synthetic form of progesterone, a female hormone that is produced naturally in the ovaries. It is used as a medication for various purposes such as:

* Preventing pregnancy when used as a birth control pill
* Treating endometriosis
* Managing symptoms associated with menopause
* Treating abnormal menstrual bleeding

Norethindrone works by thinning the lining of the uterus, preventing ovulation (the release of an egg from the ovary), and changing the cervical mucus to make it harder for sperm to reach the egg. It is important to note that norethindrone should be taken under the supervision of a healthcare provider, as it can have side effects and may interact with other medications.

Dilatation and Curettage (D&C) is a medical procedure commonly performed on the uterus. The term "dilatation" refers to the widening or opening of the cervix, which is the lower part of the uterus that opens into the vagina. This is achieved using dilators, which are gradually inserted into the cervical canal to stretch it open.

The term "curettage" refers to the scraping or suctioning out of tissue from the lining of the uterus (endometrium). A curette, a long, loop-shaped surgical instrument, is used to scrape the lining, or suction equipment may be used to remove the tissue.

A D&C procedure is typically performed to diagnose and treat various conditions affecting the uterus, such as abnormal uterine bleeding, heavy menstrual periods, endometrial hyperplasia, or to remove residual tissue after a miscarriage or abortion. It's usually a minor surgical procedure that can be done in a hospital, clinic, or doctor's office, and is often performed under local anesthesia, conscious sedation, or general anesthesia depending on the situation and patient preference.

The uterus, also known as the womb, is a hollow, muscular organ located in the female pelvic cavity, between the bladder and the rectum. It has a thick, middle layer called the myometrium, which is composed of smooth muscle tissue, and an inner lining called the endometrium, which provides a nurturing environment for the fertilized egg to develop into a fetus during pregnancy.

The uterus is where the baby grows and develops until it is ready for birth through the cervix, which is the lower, narrow part of the uterus that opens into the vagina. The uterus plays a critical role in the menstrual cycle as well, by shedding its lining each month if pregnancy does not occur.

An Intrauterine Device (IUD) is a small, T-shaped device that is inserted into the uterus to prevent pregnancy. The copper IUD is a type of long-acting reversible contraception (LARC) that releases copper ions, which are toxic to sperm and egg, preventing fertilization. It is one of the most effective forms of birth control available, with a failure rate of less than 1%.

The copper IUD can be used by women who have previously given birth as well as those who have not. It can be inserted up to five days after unprotected intercourse as emergency contraception to prevent pregnancy. Once inserted, the copper IUD can remain in place for up to ten years, although it can be removed at any time if a woman wants to become pregnant or for other reasons.

Copper IUDs are also used as an effective treatment for heavy menstrual bleeding and can be used to manage endometriosis-associated pain. Common side effects of copper IUDs include heavier and longer menstrual periods, cramping during insertion, and irregular periods during the first few months after insertion. However, these side effects usually subside over time.

It is important to note that while copper IUDs are highly effective at preventing pregnancy, they do not protect against sexually transmitted infections (STIs). Therefore, it is still recommended to use condoms or other barrier methods of protection during sexual activity to reduce the risk of STIs.

Dysmenorrhea is a medical term that refers to painful menstrual cramps and discomfort during menstruation. It's one of the most common gynecological complaints among women of reproductive age. There are two types of dysmenorrhea: primary and secondary.

1. Primary Dysmenorrhea: This type is more common and occurs in women who have had normal, pelvic anatomy. The pain is caused by strong contractions of the uterus due to the production of prostaglandins (hormone-like substances that are involved in inflammation and pain). Primary dysmenorrhea usually starts soon after menarche (the beginning of menstruation) and tends to improve with age, particularly after childbirth.
2. Secondary Dysmenorrhea: This type is less common and occurs due to an underlying medical condition affecting the reproductive organs, such as endometriosis, uterine fibroids, pelvic inflammatory disease (PID), or adenomyosis. The pain associated with secondary dysmenorrhea tends to worsen over time and may be accompanied by other symptoms like irregular menstrual bleeding, pain during intercourse, or chronic pelvic pain.

Treatment for dysmenorrhea depends on the type and underlying cause. For primary dysmenorrhea, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen can help alleviate pain by reducing prostaglandin production. Hormonal birth control methods like oral contraceptives and intrauterine devices (IUDs) may also be prescribed to reduce menstrual pain. For secondary dysmenorrhea, treatment typically involves addressing the underlying medical condition causing the pain.

The treatment is determined based on the cause of menorrhagia. In case of puberty menorrhagia due to immaturity of hypothalamic ... Excessive menstruation between puberty and 19 years of age is called puberty menorrhagia. Excessive menstruation is defined as ... The most common physiological reason for puberty menorrhagia is the immaturity of hypothalamic-pituitary-ovarian axis, leading ... The most common cause for puberty menorrhagia is dysfunctional uterine bleeding. The other reasons are idiopathic ...
Weeks AD (March 2000). "Menorrhagia and hypothyroidism. Evidence supports association between hypothyroidism and menorrhagia". ... "Menorrhagia (heavy menstrual bleeding) - Symptoms and causes". Mayo Clinic. Retrieved 2022-09-10. "Abnormal Uterine Bleeding". ... "Menorrhagia (heavy menstrual bleeding) - Diagnosis and treatment - Mayo Clinic". www.mayoclinic.org. Retrieved 2022-09-10. ... Reid PC, Mukri F (April 2005). "Trends in number of hysterectomies performed in England for menorrhagia: examination of health ...
... menorrhagia; and intraretinal and intracranial bleeding. Excessive numbers of platelets, and/or normal platelets responding to ...
However, up to 20% of women experience much heavier bleeding, or menorrhagia. This excess blood loss can lead to anemia, with ... Apgar, Barbara S.; Kaufman, Amanda H.; George-Nwogu, Uche; Kittendorf, Anne (2007-06-15). "Treatment of Menorrhagia". American ... menorrhagia (excessive menstrual bleeding), menstruation-related or fibroid-related anemia and dysmenorrhea (painful ...
"Menorrhagia (Heavy Menstrual Bleeding)". The Mayo Clinic. Retrieved 5 May 2013. "Hirsutism and Polycystic Ovary Syndrome (PCOS ... Oral contraceptives are prescribed in the treatment of menorrhagia to help regulate menstrual cycles and prevent prolonged ... menstrual disorders such as dysmenorrhea and menorrhagia, and hirsutism. Hormonal treatments, such as hormonal contraceptives, ...
Clemetson CA (1969) "Menorrhagia rheumatica." La Vie Medicale, No Hors Serie, Decembre, pp 1-10: Symposium International - ... Alan C, Clemetson CA, Blair LM (May 1962). "Capillary strength of women with menorrhagia". American Journal of Obstetrics and ...
Some scholars view it as menorrhagia; others as haemorrhoids. Because of the continual bleeding, the woman would have been ...
The condition can also be distinguished from polymenorrhagia, which is a combination of polymenorrhea and menorrhagia (heavy ... Goldstein SR (February 2004). "Menorrhagia and abnormal bleeding before the menopause". Best Pract Res Clin Obstet Gynaecol. 18 ...
Menorrhagia Treated by Intensive X-Ray Therapy. 1923. Treatment of Cancer of the Breast. 1945. The Artificial Menopause. 1945. ...
Melena, hematemesis, hematuria, menorrhagia or hematochezia point to blood loss. Elderly deconditioned patients, especially ...
Women with this deficiency experience menorrhagia: prolonged, abnormal heavy menstrual bleeding. This is typically a symptom of ...
Use of IUDs have also shown to reduce menorrhagia and dysmenorrhea. Gonadotropin-releasing hormone (GnRH) modulators, including ...
Sudden heavy flows or amounts greater than 80 ml are termed menorrhagia. Heavy menstruation that occurs frequently and ... menorrhagia (excessive menstrual bleeding), menstruation-related or fibroid-related anemia and dysmenorrhea (painful ...
Adult females may experience menorrhagia (heavy periods) due to the bleeding tendency. The pattern of inheritance is criss- ...
It has also been used - mostly off-label - for other indications, namely in the management of menorrhagia, fibrocystic breast ... Although not currently a standard treatment for menorrhagia, danazol demonstrated significant relief in young women with ... "Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age". Fertility and Sterility. 92 (4): 1351-1354 ... menorrhagia in a study, and, because of a lack of a significant adverse effects, it was proposed as an alternative treatment. ...
... has also been used to shrink uterine fibroids and to reduce menorrhagia. Due to its antigonadotropic effects and ... Roy SN, Bhattacharya S (2004). "Benefits and risks of pharmacological agents used for the treatment of menorrhagia". Drug ...
... has also been tested in experimental setting as a treatment for menorrhagia. use in treatment of mastalgia and ... Kriplani A, Kulshrestha V, Agarwal N (August 2009). "Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot ...
It may represent a possible endocrine dysfunction, resulting in menorrhagia or metrorrhagia. Mid-cycle bleeding may indicate a ...
Amenorrhea and menorrhagia have been reported as side effects of nandrolone cypionate. Nandrolone theoretically may produce ...
Epistaxis, petechiae and ecchymoses are common symptoms, as are subconjunctival bleeding and menorrhagia. On average, bleeding ...
Sharp, Howard T. (October 2006). "Assessment of New Technology in the Treatment of Idiopathic Menorrhagia and Uterine ...
Oral contraception can assist with management of various medical conditions, such as menorrhagia. However, oral contraceptives ...
Some patients have spontaneous mucosal bleeding, such as menorrhagia, epistaxis, and gum bleeding. Severe and life-threatening ...
It is commonly used to treat gynecological disorders such as dysmenorrhea and menorrhagia. Botanic Gardens Conservation ...
Amenorrhea: a total cessation of the menstrual period Menorrhagia: unusually heavy periods thefreedictionary.com > ...
Patients with adenomyosis often present with painful menses (dysmenorrhea), profuse menses (menorrhagia), or both. Other ...
Menorrhagia (meno = prolonged, rrhagia = excessive flow/discharge) is an abnormally heavy and prolonged menstrual period. ...
Endometrial ablation devices are used for the treatment of menorrhagia due to dysfunctional uterine bleeding. As the popularity ...
It is thus a combination of metrorrhagia (intermenstrual bleeding) and menorrhagia (heavy/prolonged menstrual bleeding). It can ...
It is the opposite of heavy periods or hypermenorrhea which is more properly called menorrhagia. In some women it may be normal ...
The treatment is determined based on the cause of menorrhagia. In case of puberty menorrhagia due to immaturity of hypothalamic ... Excessive menstruation between puberty and 19 years of age is called puberty menorrhagia. Excessive menstruation is defined as ... The most common physiological reason for puberty menorrhagia is the immaturity of hypothalamic-pituitary-ovarian axis, leading ... The most common cause for puberty menorrhagia is dysfunctional uterine bleeding. The other reasons are idiopathic ...
Menorrhagia is defined as menstruation at regular cycle intervals but with excessive flow and duration and is one of the most ... Complications of menorrhagia include the following:. * Treatment of menorrhagia must be individualized to treat each patients ... Any woman of reproductive age who is menstruating may develop menorrhagia. Most patients with menorrhagia are older than 30 ... encoded search term (Menorrhagia) and Menorrhagia What to Read Next on Medscape ...
Student homeopath Julia Gunes Bayram shares a case of hot flashes and menorrhagia in a premenopausal womam of 50. ... March 10, 2021) Sam, fit lady in her 50s, 42 kgs and 1.52cm had menorrhagia that lasted for 2-3 months with irregular and ... Student homeopath Julia Gunes Bayram shares a case of hot flashes and menorrhagia in a premenopausal womam of 50. ... Hot Flashes, Menorrhagia in Pre-Menopausal Woman of 50. February 18, 2023 ...
What is hysterectomy for menorrhagia?. admin. September 13, 2019. What is hysterectomy for menorrhagia?. The hysterectomy ... What does menorrhagia mean?. Menorrhagia is heavy or prolonged menstrual bleeding. Many women have this type of abnormal ... Does menorrhagia require surgery?. You may need surgical treatment for menorrhagia if medical therapy is unsuccessful. ... Menorrhagia is recognised as a medical condition and it is treatable. Your GP can discuss the available treatment options with ...
How do you know if you have menorrhagia? When should you see a doctor? And how do you treat it? We have the answers. ... Is menorrhagia normal?. Menorrhagia is more common than you think; it affects more than 10 million American women each year.1 ... What is menorrhagia, exactly?. Actually, your first question could be, "How do I pronounce menorrhagia?" Its pronounced "meh- ... You may not be familiar with the word menorrhagia, but you might be familiar with what it means. Menorrhagia is menstrual ...
Pradrantak Churna and Naari Kalyan Churna for ayurvedic and natural treatment of menorrhagia (heavy menstrual bleeding). These ... About Menorrhagia. Menorrhagia is related to menstrual period in which women experience heavy menstrual bleeding and is called ... Causes of Menorrhagia. *Hormonal imbalance: There are two main hormones that regulates the functioning of the vagina namely ... Diagnosis of Menorrhagia. *Evaluation of the cervical infection. *Ultrasound can be done to evaluate pelvis organs including ...
Menorrhagia is diagnosed when you have a regular cycle but the menstrual bleeding lasts longer than usual while ... What is menorrhagia and menometrorrhagia?. Heavy menstrual bleeding is also known as "menorrhagia". Menorrhagia is diagnosed ... Menorrhagia can be normal, but it can also be a sign of a problem. Menometrorrhagia is menorrhagia, heavy bleeding, that is ... Heavy bleeding (menorrhagia) affects more than 10 million American women each year and is one of the most common problems women ...
Menorrhagia) treatment in Estero, FL. Treatment for menstrual cramps and menorrhagia. ... Causes of Menorrhagia. There can be many different causes for menorrhagia, which can make it frustrating to deal with. That ... Menorrhagia Treatment. Menorrhagia is treatable. Any treatment plan will typically begin with diagnosis to determine the root ... Menorrhagia can be frustrating and debilitating. Request information about menorrhagia treatment today: Call (239) 425-2900 or ...
... is heavy or prolonged bleeding during your period. It can be caused by hormone problems or problems with the uterus ...
Menorrhagia is most common amongst teens and perimenopausal women. If you think you are suffering from menorrhagia, contact ... Menorrhagia is the official name for recurrent heavy periods. This is characterised by a loss of more than 80ml during each ...
Heavy periods are very common and nearly 50% of women suffer from heavy periods at some stage of their life. There can be many reasons for heavy periods and its important to understand the underlying cause.
... or menorrhagia, is probably the most common causes menorrhagia! This since age 12 now 35 long history of oral use in first! The ... or menorrhagia, is probably the most important first in! Effective in cases of menorrhagia that are due to STIs to functional ... Found intravenous and intramuscular injections to be effective in cases of menorrhagia that are due to STIs menorrhagia the! - ... Used for menorrhagia - excessively heavy periods, balances this out. So I found out that the dosage on the label for me that ...
Heavy periods (or menorrhagia) may be hard to define, but if you feel you are using more tampons or sanitary towels than usual ... If you have menorrhagia from taking hormone medication, you and your doctor may be able to treat the condition by changing or ... Menorrhagia. Every woman is different, which means the amount of blood lost during a menstrual period differs from person to ... Medical therapy for menorrhagia may include:. *Nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs, such as ibuprofen ( ...
Menorrhagia or heavy menstrual bleeding (HMB) is the most common gynecologic problem encountered in primary care. ... Menorrhagia or heavy menstrual bleeding (HMB) is the most common gynecologic problem encountered in primary care. It wreaks ... Menorrhagia: Current Management Approaches. Aug 28, 2017. Jeannette Y Wick, RPh, MBA, FASCP ... Menorrhagia or heavy menstrual bleeding (HMB) is the most common gynecologic problem encountered in primary care. ...
Menorrhagia. Menorrhagia is very heavy menstrual bleeding. Typical periods produce 2 to 3 tablespoons of menstrual blood. ... People with menorrhagia can produce more than twice that amount. More than 10 million. American women have this condition, ... https://www.cdc.gov/ncbddd/blooddisorders/women/menorrhagia.html. *. Hormes JM, et al. (2017). Does culture create craving? ...
ရာသီသွေးဆင်းများခြင်း၊ပုံမှန်မဟုတ်ပဲ သွေးဆင်းခြင်း အမျိုးသမီးတစ်ယောက် အပျိုဖော်စဝင်ပြီဆိုတာနဲ့ လစဉ် မျိုးဥကြွေခြင်း၊ဓမ္မတာလာခြင်း အစရှိတဲ့အရာတွေကို ကြုံတွေ့ရမှာမလွဲမသွေပါ။ဒီဖြစ်စဉ်တွေဟာ ပုံမှန်တွေ့ကြုံနေရမှာပဲ ဖြစ်ပါတယ်။ထိုအရာတွေထဲကမှ ဓမ္မတာလာချိန် သွေးဆင်းများခြင်း၊ပုံမှန် မဟုတ်ပဲ သွေးဆင်းခြင်းအကြောင်းကို ပြောပြခြင်ပါတယ်... အမျိုးသမီးအများစုမှာ
The clots passed with menorrhagia perhaps indicate 585 viewsannuv7735 Asked question August 2, 2021. Gynecologygynecology ...
keywords = "menorrhagia, quality of life, systematic review",. author = "Clark, {T. Justin} and Khan, {Khalid S.} and Richard ... Quality of life instruments in studies of menorrhagia: a systematic review. T. Justin Clark, Khalid S. Khan, Richard Foon, ... Clark, TJ, Khan, KS, Foon, R, Pattison, HM, Bryan, S & Gupta, JK 2002, Quality of life instruments in studies of menorrhagia: ... Quality of life instruments in studies of menorrhagia: a systematic review. / Clark, T. Justin; Khan, Khalid S.; Foon, Richard ...
Menorrhagia and polymenorrhoea. 7089.0. History of Menorrhagia and polymenorrhoea. 1573.00. H/O: menorrhagia. Menorrhagia and ... Menorrhagia and polymenorrhoea. H/O: menorrhagia. 1573.00. 1077.0. Diagnosis of Menorrhagia and polymenorrhoea. Menorrhagia and ... Menorrhagia and polymenorrhoea. 35691.0. Diagnosis of Menorrhagia and polymenorrhoea. K592000. Menorrhagia. Menorrhagia and ... Menorrhagia and polymenorrhoea. Menorrhagia. K592000. 15022.0. Diagnosis of Menorrhagia and polymenorrhoea. Menorrhagia and ...
Menorrhagia can occur for many reasons, but in the absence of any true pathology ... Menorrhagia is the technical medical term for heavy menstrual bleeding. ... What is Menorrhagia?. by Jennifer Bunn, RN. Menorrhagia is the technical medical term for heavy menstrual bleeding. Menorrhagia ... Many women do not seek help for menorrhagia, believing that it is normal. If menorrhagia interferes with quality of life or ...
Are your breasts so sensitive you flinch at the idea of your partner touching them? Are they heavy, cause discomfort or feel like they will burst out of your bra during your cycle? Maybe your period is so…. READ MORE ...
... resources for gynecologists and healthcare teams to use Cerene Cryotherapy in-office endometrial cryoablation for menorrhagia. ...
Protected: Menorrhagia in Premenopausal Patient. Posted on February 10, 2023. by Yago Stecher ...
What is Menorrhagia? Menorrhagia is a condition described as abnormally heavy or prolonged bleeding. Although heavy menstrual ... What are the treatment options for Menorrhagia? The treatment for menorrhagia factors in various conditions of your health. ... What are the causes of Menorrhagia? The common causes associated with menorrhagia are hormonal imbalances, malfunctioning of ... With menorrhagia, it becomes difficult to maintain the usual activities during the periods because of the excessive blood loss ...
TEXT REVIEW OF PUBERTAL MENORRHAGIA DEFINITION- Puberty menorrhagia is a threshold bleeding of adolescense caused by excess or ... CASE REVIEW OF PUBERTAL MENORRHAGIA A 14 year girl complained of increased pv bleeding in her 2nd menstrual cycle,associated ... If the menorrhagia is secondary to ITP, hypothyroidism, we have to treat the underlying cause as well. ...

No FAQ available that match "menorrhagia"

No images available that match "menorrhagia"